Could a failed ulcer drug help regrow insulin cells in type 1 diabetes?
NCT ID NCT06474598
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase 2 trial is testing a drug called MTX228 (Tolimidone) in 24 adults with type 1 diabetes who still produce some insulin. The goal is to see if the drug can help regrow the beta cells that make insulin, which could lower the amount of insulin they need to inject and improve blood sugar control. Researchers will compare different doses to find the most effective one for a future larger study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MTX228 (Tolimidone)
What this could lead to
If successful, this could point toward a treatment that helps people with type 1 diabetes produce some of their own insulin again, reducing their need for injected insulin.
What could go wrong
This is a small, early-phase trial with only 24 participants, so results may not apply widely. The drug previously failed for other conditions, and its effect on beta-cell regrowth is unproven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
University of Alberta
RECRUITINGEdmonton, Alberta, T6G 2R3, Canada
Contact Email: •••••@•••••
Contact Email: •••••@•••••